product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
KGF/FGF-7 Antibody (001) [DyLight 405]
catalog :
NBP2-90560V
quantity :
0.1 ml
price :
539 USD
clonality :
monoclonal
host :
domestic rabbit
conjugate :
DyLight 405
clone name :
001
reactivity :
human, mouse
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP2-90560V
SKU :
NBP2-90560V
product name :
KGF/FGF-7 Antibody (001) [DyLight 405]
sizes available :
0.1 ml
description :
The KGF/FGF-7 Antibody (001) [DyLight 405] from NBP2-90560V is a 6.7e-05 antibody to . This antibody reacts with mouse.
target :
KGF/FGF-7
category :
Primary Antibodies
buffer :
50mM Sodium Borate
clonality :
Monoclonal
clone :
001
conjugate :
DyLight 405
all_available conjugate :
PerCP;mFluor Violet 610 SE;Alexa Fluor 350;mFluor Violet 500 SE;CoraFluor 1;DyLight 755;DyLight 405
dilution :
ELISA
host :
Rabbit
immunogen :
This antibody was obtained from a rabbit immunized with purified, recombinant Mouse KGF/FGF-7 (Accession#: NP_032034.1; Cys32-Thr194).
isotype :
IgG
purity :
Protein A purified
species :
Mouse
gene symbol :
FGF7
applications :
ELISA
extended description :
Recombinant Monoclonal Antibody
USD :
539 USD
product details :
Recombinant Monoclonal Antibody
alt names :
FGF-7, fibroblast growth factor 7HBGF-7, Heparin-binding growth factor 7, keratinocyte growth factor, KGFfibroblast growth factor 7 (keratinocyte growth factor)
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments
